Literature DB >> 11961078

Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist.

Katrin Zahn1, Niels Eckstein, Christian Tränkle, Wolfgang Sadée, Klaus Mohr.   

Abstract

Previous studies on allosteric interactions at muscarinic receptors have often focused on ligand-receptor binding interactions, because ligand binding seemed to reflect functional consequences. The prototypal allosteric agent alcuronium is known to bind with similar affinity to the M(2) subtype of muscarinic acetylcholine receptors whether or not the receptors are occupied by the agonist pilocarpine. To determine allosteric modulation of receptor signaling by alcuronium, the effects of pilocarpine were measured in contracting guinea pig left atria and on G-protein coupling in M(2)-transfected Chinese hamster ovary (CHO) cell membranes. Alcuronium dose-dependently suppressed pilocarpine-induced reduction of isometric contraction force in atria (pIC(50, Alc) = 5.63) without any effect on the EC(50) of pilocarpine, consistent with an allosteric mechanism. In contrast, alcuronium shifted the concentration-effect curve of the agonist oxotremorine M to the right without affecting the maximal effect, in a formally competitive manner (pK(A, Alc) = 5.54). If pilocarpine remained receptor bound in the presence of alcuronium, this indicates that pilocarpine can no longer act as an agonist. In support of this hypothesis, pilocarpine acted as a competitive antagonist against oxotremorine M in the presence of 10 microM alcuronium. Measuring guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPgammaS) binding in CHO-M(2) membranes yielded similar results. Alcuronium suppressed pilocarpine-induced stimulation of [(35)S]GTPgammaS binding (pIC(50, Alc) = 5.47) without shift in EC(50), whereas it competitively shifted the response to oxotremorine M (pK(A, Alc) = 5.97). [(3)H]Oxotremorine M binding data corresponded with the functional findings. In conclusion, alcuronium converted the agonist pilocarpine into an antagonist-a novel type of functional allosteric interaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961078     DOI: 10.1124/jpet.301.2.720

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  DFT calculation of four new potential agents muscarinic of bispyridinium type: structure, synthesis, biological activity, hydration, and relations with the potents W84 and DUO-3O.

Authors:  M Alcolea Palafox; P Posada-Moreno; A L Villarino-Marín; C Martinez-Rincon; I Ortuño-Soriano; I Zaragoza-García
Journal:  J Comput Aided Mol Des       Date:  2010-12-22       Impact factor: 3.686

2.  Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.

Authors:  Maren Grossmüller; Johannes Antony; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-16       Impact factor: 3.000

3.  Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

Authors:  Karen J Gregory; Nathan E Hall; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

Review 4.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Cooperative interactions at M2 muscarinic acetylcholine receptors: structure/activity relationships in stepwise shortened bispyridinium- and bis(ammonio)alkane-type allosteric modulators.

Authors:  Ralf Gilsbach; Maren Grossmüller; Vildan Alptüzün; Ercin Erciyas; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

6.  PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

Authors:  J G Horswill; U Bali; S Shaaban; J F Keily; P Jeevaratnam; A J Babbs; C Reynet; P Wong Kai In
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

7.  Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors.

Authors:  Mark Bauer; Andrea Chicca; Marco Tamborrini; David Eisen; Raissa Lerner; Beat Lutz; Oliver Poetz; Gerd Pluschke; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

8.  Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.

Authors:  Zhan-Guo Gao; Kai Ye; Anikó Göblyös; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  BMC Pharmacol       Date:  2008-12-12

9.  Allosteric modulation of muscarinic acetylcholine receptors.

Authors:  Karen J Gregory; Patrick M Sexton; Arthur Christopoulos
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

10.  RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents.

Authors:  I-Shan Chen; Kazuharu Furutani; Atsushi Inanobe; Yoshihisa Kurachi
Journal:  J Physiol       Date:  2014-01-13       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.